Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) was the recipient of a significant increase in short interest in December. As of December 30th, there was short interest totalling 4,740,000 shares, an increase of 11.8% from the December 15th total of 4,240,000 shares. Based on an average daily volume of 951,300 shares, the short-interest ratio is presently 5.0 days. Currently, 4.6% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ARWR. StockNews.com began coverage on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 12th. They set a "hold" rating for the company. HC Wainwright cut their target price on shares of Arrowhead Pharmaceuticals from $110.00 to $90.00 and set a "buy" rating for the company in a research note on Tuesday, December 6th. Chardan Capital cut their target price on shares of Arrowhead Pharmaceuticals from $82.00 to $60.00 in a research note on Tuesday, January 10th. SVB Leerink dropped their price objective on shares of Arrowhead Pharmaceuticals from $33.00 to $31.00 and set a "market perform" rating for the company in a research note on Tuesday, November 29th. Finally, B. Riley dropped their price objective on shares of Arrowhead Pharmaceuticals from $65.00 to $59.00 and set a "buy" rating for the company in a research note on Wednesday, November 30th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $59.22.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, Director William D. Waddill sold 3,200 shares of the stock in a transaction on Monday, January 9th. The shares were sold at an average price of $30.00, for a total value of $96,000.00. Following the completion of the sale, the director now directly owns 28,950 shares of the company's stock, valued at $868,500. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, COO Patrick O'brien sold 17,500 shares of the firm's stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $38.33, for a total transaction of $670,775.00. Following the completion of the transaction, the chief operating officer now directly owns 363,375 shares of the company's stock, valued at $13,928,163.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William D. Waddill sold 3,200 shares of the firm's stock in a transaction on Monday, January 9th. The shares were sold at an average price of $30.00, for a total transaction of $96,000.00. Following the transaction, the director now directly owns 28,950 shares of the company's stock, valued at $868,500. The disclosure for this sale can be found here. Insiders sold a total of 109,966 shares of company stock valued at $4,050,435 over the last three months. Corporate insiders own 3.20% of the company's stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Trading Down 3.1 %

Arrowhead Pharmaceuticals stock opened at $32.70 on Tuesday. The firm has a 50-day moving average price of $33.89 and a 200-day moving average price of $36.57. The firm has a market capitalization of $3.47 billion, a PE ratio of -19.46 and a beta of 1.26. Arrowhead Pharmaceuticals has a 12-month low of $26.81 and a 12-month high of $56.25.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last released its earnings results on Monday, November 28th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.24). The firm had revenue of $31.58 million during the quarter, compared to the consensus estimate of $107.60 million. Arrowhead Pharmaceuticals had a negative return on equity of 40.23% and a negative net margin of 71.01%. As a group, sell-side analysts predict that Arrowhead Pharmaceuticals will post -0.86 earnings per share for the current fiscal year.

About Arrowhead Pharmaceuticals

(Get Rating)

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC.

Recommended Stories

• Get a free copy of the StockNews.com research report on Arrowhead Pharmaceuticals (ARWR)
• Is the Worst Behind for Under Armor Stock with a New CEO?
• Analysts Like The Fit Of Skechers USA
• What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
• Can We Trust The Rally In The S&P 500
• Energy Surge: Four Oil-And-Gas Stocks Setting Up In Bullish Bases

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.